In summary, TPC2 loss not only suppresses proliferative signalling but also enhances tumour immunogenicity, immunogenicity by an increase in MHC-1 expression and decrease in PD-L1 expression, particularly in HCC. The gene discussed is TPCN2; the disease is hepatocellular carcinoma.